US Patent 4237140 - Analgesic mixture of nalbuphine and acetaminophen

Related Patents

	4777174 - Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same - Owned by Analgesic Associates (Larchmont, NY) Novel analgesic and anti-inflammatory compositions of matter for use in eliciting an analgesic or anti-inflammatory response, said compositions comprising caffeine together with a selected non-narcotic analgesic/nonsteroidal anti-inflammatory drug or a selected narcotic analgesic, or both, are disclosed. When used in combination with the selected drugs, caffeine enhances the analgesic or anti-inflammatory response and also hastens its onset.
	4656177 - Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same - Owned by Analgesic Associates (Larchmont, NY) Novel analgesic and anti-inflammatory compositions of matter for use in eliciting an analgesic or anit-inflammatory response, said compositions comprising caffeine together with a selected non-narcotic analgesic/nonsteroidal anti-inflammatory drug or a selected narcotic analgesic, or both, are disclosed. When used in combination with the selected drugs, caffeine enhances the analgesic or anti-inflammatory response and also hastens its onset.
	4404208 - Analgesic mixture of nalbuphine and tiflamizole - Owned by E. I. Du Pont de Nemours and Company (Wilmington, DE) Pharmaceutical compositions of nalbuphine and tiflamizole have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.
	4407805 - Analgesic mixture of nalbuphine and zomepirac - Owned by E. I. Du Pont de Nemours and Company (Wilmington, DE) Pharmaceutical compositions of nalbuphine and zomepirac have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.
	4402962 - Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole - Owned by E. I. Du Pont de Nemours and Company (Wilmington, DE) Pharmaceutical compositions of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.